In addition, since in KRAS mutant cells, B-raf inhibition activates upstream proteins leading to ERK activation through an alternative pathway, sorafenib should not be used as single-agent therapy in KRAS-mutated cancers [23,71], and nanoparticles offer the possibility for simultaneous delivery of different agents. The gene discussed is KRAS; the disease is cancer.